ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OKUR / insiders
CLLS (45) ANIX (37) PMVP (42) EQ (31) ⌘ Pro Terminal →

OnKure Therapeutics Inc. (Class A) (OKUR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.59 -1.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.58

OnKure Therapeutics Inc. (Class A) (OKUR) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $104.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OKUR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OKUR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, OnKure Therapeutics Inc. (Class A) (NASDAQ: OKUR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.59 (-1.14% 1D, market cap $104.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, OKUR ranks #634 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OKUR compare to CLLS and ANIX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OKUR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLLS (Cellectis S.A.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $104.0M) and ANIX (Anixa Biosciences Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $103.9M). Among the 5-stock peer group, OKUR leads on earnings multiple (N/A) while OKUR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OKUR?
▼

Per OKUR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001637715), OnKure Therapeutics Inc. (Class A) generated $176.3M in revenue (+15.7% YoY), -$59.5M in net income, and -$51.9M in free cash flow against $62.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.58 (-0.40%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (7)Whales (5)SEC (10)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$6 Bull$2 Base$2 Bear
📬 FREE OKUR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OKUR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY OKUR SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$2.25+2.2% Next Q
Q2 (-2Q)
29
Grade E$2.30+14.3% Next Q
Q3 (-1Q)
31
Grade E$2.63-1.5% Next Q
Current
34
Grade E$2.59-8.7% Hist 90D α
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OKUR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OKUR currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.83) and Max Pain ($2.72) forces dealer call-delta covering toward $5.65.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OKUR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OKUR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

OKUR Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (OKUR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on OKUR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OKUR)

  • ✓Walkthrough of OKUR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OKUR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.70%▼ DESCENDING CHANNEL
2026-11-04O $2.62H $2.62L $2.59C $2.59VOL 500.8K
RES: $3.83SUP: $1.69SMA50: $2.83SMA200: $3.61
$4.98$4.18$3.37$2.57$1.76RES $3.83SUP $1.69$2.592026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OKUR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OKUR Butterfly Map → + Track OKUR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +15.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OKUR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OKUR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OKUR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OKUR)

Health Care Rank #634 of 1015 ⚔️ CLLS vs OKUR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OKUR vs. CLLS, ANIX, PMVP, EQ)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, OnKure Therapeutics Inc. (Class A) (OKUR) ranks #634 by composite RQD confidence (34/100, grade E) and #643 by equity capitalization ($104.9M). Within this direct 5-issuer industry benchmark cohort, OKUR leads on earnings valuation at N/A trailing P/E, while OKUR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CLLS currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with OKUR at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OKUR ACTIVE
OnKure Therapeutics Inc. (Class A)
E 34/100 — — -35.0% -1.14% $104.9M Benchmark Subject
CLLS
Cellectis S.A.
D 45/100 — — — -4.17% $104.0M /clls-vs-okur →
ANIX
Anixa Biosciences Inc.
D- 37/100 — — -35.0% -4.17% $103.9M /anix-vs-okur →
PMVP
PMV Pharmaceuticals Inc.
D- 42/100 — — -35.0% +4.58% $103.5M /pmvp-vs-okur →
EQ
Equillium Inc.
E 31/100 — — -35.0% +0.73% $108.1M /eq-vs-okur →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001637715 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OnKure Therapeutics Inc. (Class A) (OKUR) reported GAAP revenue of $176.3M (+15.7% vs. FY2024 revenue of $152.3M , and +70.4% cumulative change since FY2023) , GAAP net income of -$59.5M, operating cash flow of -$51.8M, and free cash flow of -$51.9M (-1.4% YoY). On the balance sheet, OKUR closed FY2025 with $62.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $176.3M -$59.5M -$51.8M -$51.9M $62.1M —
FY2024 (FY) 2024-12-31 $152.3M -$52.7M -$51.1M -$51.2M $114.9M —
FY2023 (FY) 2023-12-31 $103.4M -$35.3M -$34.5M -$34.5M — —

3. OKUR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OKUR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, OnKure Therapeutics Inc. (Class A) (NASDAQ: OKUR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.59 (-1.14% 1D, market cap $104.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, OKUR ranks #634 in composite RQD confidence.

How does OKUR compare to CLLS and ANIX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OKUR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CLLS (Cellectis S.A.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $104.0M) and ANIX (Anixa Biosciences Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $103.9M). Among the 5-stock peer group, OKUR leads on earnings multiple (N/A) while OKUR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OKUR?

Per OKUR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001637715), OnKure Therapeutics Inc. (Class A) generated $176.3M in revenue (+15.7% YoY), -$59.5M in net income, and -$51.9M in free cash flow against $62.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OKUR trading relative to its 50-day, 200-day, and 52-week technical levels?

OKUR last traded at $2.59 (-1.14% on volume of 500,843 shares), positioning the stock -8.48% below its 50-day simple moving average ($2.83) and -28.25% below its 200-day simple moving average ($3.61). Across its 52-week range of $2.01 to $5.38, OKUR sits at the 17.2% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.27 to $2.91).

Direct Sub-Reports: OKUR RQD Cockpit OKUR 12M Forecast OKUR Earnings & Move OKUR Dividends & DRIP OKUR Insiders & 13F OKUR Whale Options OKUR Profit Sankey OKUR News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

OKUR — OnKure Therapeutics Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

OnKure Therapeutics Inc. (Class A) (OKUR) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.59 (-1.14% 1D, market capitalization $104.9M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

OnKure Therapeutics Inc. (Class A) is listed on NASDAQ under the ticker OKUR. It operates in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — in each of the listed fiscal years, so the company's current income is derived from no sales.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), OnKure Therapeutics Inc. (Class A) (OKUR) reported $176.3M in annual revenue (up from $152.3M in FY2024, +15.7% YoY) and -$59.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($103.4M revenue, -$35.3M net income) through FY2025, OKUR scaled operating cash flow to -$51.8M and free cash flow to -$51.9M, backed by $62.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $2.01 – $5.38 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), OKUR carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can OKUR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $176.3M and free cash flow of -$51.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is OKUR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OKUR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for OnKure Therapeutics Inc. (Class A) (OKUR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OKUR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OKUR Bull vs. Bear Conversation Board — What's Your Call at $2.59?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OKUR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OKUR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $3.14 (+19.8%)
📌 Pinned Debate

Cash of $59.0M at FY 2025 provides a funded balance sheet alongside a 2.5 Altman Z-Score, though the source does not tie this to a pipe

Long OKUR at $2.62 targeting $3.14. Cash of $59.0M at FY 2025 provides a funded balance sheet alongside a 2.5 Altman Z-Score, though the source does not tie this to a pipeline.. Institutional whale score is 5/20 and the risk/reward vs. the $2.01 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@ShortSeller_Dan Shorting a 5/20 institutional whale-flow stock at $2.62 is dangerous when funds are rotating into Health Care.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $1.99 (-24.0%)
Spot @ $2.62

Zero revenue, a -35% ROIC, a 0% FCF yield, and a 2/9 Piotroski F-Score point to a loss-making business with weak cash generation.

Sitting on the sidelines or leaning short OKUR above $2.62. Zero revenue, a -35% ROIC, a 0% FCF yield, and a 2/9 Piotroski F-Score point to a loss-making business with weak cash generation.. Until Fundamental Cash Engine (7/20) and FCF yield (0.0%) inflect higher, upside is capped near $5.38.

LIVE TAPE